eurekalert.org
UH researchers discover potential breakthrough for Crohn's disease treatment - EurekAlert!
This study suggests a different treatment target for Crohn’s disease: fixing damaged intestinal lining rather than only suppressing inflammation. If validated in humans, repurposed cancer drugs could speed development of therapies that help the gut barrier heal.
Patients with Crohn's disease, clinicians treating IBD, and researchers working on epithelial biology, drug repurposing, or translational gastroenterology.
What To Know
What To Know University of Houston-led researchers report lab findings that Crohn’s disease may be driven by persistent stress signaling in intestinal epithelial cells that prevents normal repair.
In patient-derived organoids, low doses of two existing cancer drugs (pazopanib and ponatinib) reduced that stress signaling and cell death, and promoted epithelial regeneration.
The team frames this as shifting focus from immune suppression to restoring the gut barrier, and highlights the potential advantage of repurposing FDA-approved cancer drugs to shorten development time. The work used patient-derived organoids and was published in Gastro Hep Advances.
This is preclinical research (lab and organoid experiments) describing a possible therapeutic approach; it does not report results from human clinical trials or change current treatment recommendations.
Who Should Pay Attention Patients with Crohn’s disease and IBD interested in emerging research on gut barrier repair; clinicians and researchers studying epithelial biology, drug repurposing, or translational therapies. More Context The findings are based on laboratory experiments and patient-derived organoids, not clinical trial data.
Repurposed drugs showing promise in preclinical models often need additional safety and efficacy testing in humans before becoming treatment options. The EurekAlert! release is a university press release summarizing the study.
Early-stage, preclinical research using patient-derived organoids; results do not equal clinical efficacy yet and further trials would be needed. The article is a university press release summarizing a study published in Gastro Hep Advances.
